🔗 Share this article

An underground market for unapproved weight-loss medications is being driven by social media fitness personalities and vendors on messaging platforms, according to recent findings.

Experimental Treatment Gaining Traction Via Social Media

Retatrutide, which remains in clinical trials, is being promoted by online personalities for its alleged fat-burning properties. Followers are urged to contact these accounts privately for supplier links, while also receiving discount codes.

Active Commerce on Messaging Platforms

Separately, a robust market exists on Telegram, where communities with thousands of participants share comparison images, injection guides and claims of next-day British shipping. Sellers promote the drug there before directing buyers to other platforms for purchases.

Understanding The Experimental Drug

This medication is an experimental injection developed by US drugmaker Eli Lilly. The treatment affects three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could assist patients reduce up to 25% of their body weight. Referred to as the “triple G”, the substance is being hailed digitally as the successor to Ozempic.

Healthcare Professionals Express Concerns

Nevertheless, doctors and chemists have cautions that the distribution of what remains an unlicensed drug in the UK is worrisome and could result in individuals injecting products of uncertain source.

Several experts stated the demand for the experimental drug could be linked to the rising price of licensed weight loss treatments such as Mounjaro.

Legal Status and Enforcement

Marketing retatrutide on TikTok or Telegram is prohibited in the UK, as it is an unlicensed medication that cannot be marketed or distributed for human use under the British medical regulations.

Several content creators attempt to circumvent the regulations by calling to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted drug, but advertising and distribution can still violate pharmaceutical, advertising, and consumer regulations, potentially leading to fines, prosecution or prison.

Service Response and Content Elimination

According to the social media company, the platform has removed violative content and prohibited associated hashtags and search suggestions. The company said it was committed to keeping the service safe and investing in strengthening compliance measures.

Online Trading Activities

Investigations also discovered groups with up to 9,000 participants marketing retatrutide using Telegram's integrated discovery tool, which functions like a public directory. Entering “retatrutide” instantly brings up channels with numerous of users, populated with images of weight loss, positive reviews and step-by-step instructions for mixing or injecting at residence.

Within minutes of entering one group, a vendor shared WhatsApp details, where the majority of purchases occur. The seller sent an guidebook and promised delivery within 48 hours. When asked whether the substance was genuine, one seller said: “You can’t be sure.” Another provided a image of a alleged testing documentation. None inquired about weight, medical conditions or past usage.

Product Details and Pricing

Inside these groups, posts show black plastic packages with Royal Mail labels, claiming to include fresh supplies. One communication read: “It took eight of us to load them this morning.”

Buyers can select between powder vials, prepared at residence with purified liquid, or ready-to-use pens usually sold at 160 pounds for 20mg. When asked how long a pen should last, vendors give conflicting responses ranging from a several days to “depends on your body”.

Platform Oversight and Safety Measures

A representative for the messaging service said it actively monitored dangerous content on its platform including material that encouraged the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.

Medical Expert Warnings

“Individuals are injecting materials they cannot confirm. Although the science behind retatrutide is sound, these online products may not contain what they advertise,” stated Jason Murphy, the director of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor linked the surge in demand to recent cost increases for authorized weight-loss medications such as Mounjaro. “With prices increasing, individuals are turning to online platforms. But counterfeit injections are highly risky. You can’t be certain what’s contained or whether the conditions they were made in was sterile,” she said.

Her staff has previously seen individuals harmed by self-injection from unverified suppliers. “We recognize the frustration, but purchasing from Telegram or WhatsApp is gambling with your well-being,” stated the doctor. “These materials could be impure or improperly measured.”

Manufacturer Statement

A representative from Eli Lilly stated retatrutide was in phase 3 research studies and had not been evaluated or approved by any regulatory agency globally. “Consequently at this time no one can sell [it] for human use,” they said, noting that any item “falsely representing itself as a Lilly experimental substance not yet approved … may subject patients to possibly significant medical dangers”.